文献
J-GLOBAL ID:202202259430295298
整理番号:22A0620691
拡大期小細胞肺癌における第三系治療としてのICI+アンロチニブ対アンロチニブ単独の安全性と有効性:後ろ向き研究【JST・京大機械翻訳】
Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
著者 (7件):
Chen Qing
(Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China)
,
Li Yan
(Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China)
,
Zhang Wenjie
(Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China)
,
Zhang Wenjie
(Weifang Medical University, Weifang, China)
,
Wang Chen
(Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China)
,
Yang Shengjie
(Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China)
,
Guo Qisen
(Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China)
資料名:
Journal of Cancer Research and Clinical Oncology
(Journal of Cancer Research and Clinical Oncology)
巻:
148
号:
2
ページ:
401-408
発行年:
2022年
JST資料番号:
T0032A
ISSN:
0171-5216
CODEN:
JCROD
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
ドイツ (DEU)
言語:
英語 (EN)